Skip to main content

Table 4 Response

From: A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

  All patients Measurable disease at trial initiation Elevated CA125
  Group A
N= 96
Group B
N= 93
Group A
N= 79
Group B
N= 80
Group A
N= 17
Group B
N= 13
CR 33 (34) 21 (23) 24 (30) 17 (21) 9 (53) 4 (31)
PR 23 (24) 26 (28) 22 (28) 24 (30) 1 (6) 2 (15)
OR 55 (57) 47 (51) 46 (58) 41 (51) 10 (59) 6 (46)
SD 16 (17) 15 (16) 15 (19) 14 (18) 1 (6) 1 (8)
PD 9 (9) 10 (11) 7 (9) 8 (10) 2 (12) 2 (15)
Early Tumor death 0 (0) 3 (3) 0 (0) 3 (4) 0 (0) 0 (0)
Treatment discontinuation prior to evaluation 4 (4) 6 (6) 2 (3) 6 (8) 2 (12) 0 (0)
NA* 17 (18) 6 (6) 9 (11) 8 (10) 2 (12) 4 (31)
  1. *NA (not assessed): in case of measurable disease no computed tomography scans after treatment; in case of CA125 elevation no CA125 value after treatment.
  2. There were no significant differences in any of the rates between the two groups; more specifically, the rates of CR (complete response), PR (partial responbse) and OR (overall response) were as follows:
  3. All patients: (P = 0.072, 0.619 and 0.309, respectively).
  4. Patients with measurable disease: (P = 0.208, 0.861 and 0.427, respectively).
  5. Patients with evaluable disease (elevated CA125 and/or effusions): (P = 0.283, 0.565 and 0.713, respectively)